单位：[1]Experimental Centre, Beijing Friendship Hospital, Capital Medical University, Beijing, China,医技科室北京市临床医学研究所实验中心首都医科大学附属北京友谊医院[2]Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China,临床科室国家中心普外分中心普外五科（综合普外科）首都医科大学附属北京友谊医院[3]National Clinical Research Center for Digestive Disease, Beijing Friendship Hospital, Capital Medical University, Beijing, China,首都医科大学附属北京友谊医院[4]Department of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, China,临床科室肿瘤中心肿瘤内科首都医科大学附属北京友谊医院[5]Office of Cancer Screening, National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Background:Colorectal cancer (CRC) comprises a large proportion of malignant tumors, and early detection of CRC is critical for effective treatment and optimal prognosis. We aimed to discover and validate serum autoantibodies for early detection of CRC. Methods:Combined with CRC-associated autoantibodies discovered by serological proteome and multiplex analyses, 26 predefined autoantibodies were evaluated in 315 samples (130 CRCs, 75 advanced adenomas, and 110 healthy controls) by protein microarray analysis. Autoantibodies with potential detection value were verified by enzyme-linked immunosorbent assays (ELISAs). Receiver operating characteristic (ROC) curve analysis was conducted to evaluate the accuracy of the biomarkers. Results:Four serum autoantibodies (ALDH1B1, UQCRC1, CTAG1, and CENPF) showed statistically different levels between patients with advanced neoplasm (CRC or advanced adenoma) and controls in microarray analysis, which were validated by ELISAs. Among the four biomarkers, the ALDH1B1 autoantibody showed the highest detection value with area under the curve (AUC) values of 0.70 and 0.74 to detect CRC and advanced adenoma with sensitivities of 75.68 and 62.31% and specificities of 63.06 and 73.87%, respectively. By combining the four biomarkers, the performance was improved with an AUC of 0.79 to detect CRC and advanced adenomas. Conclusion:The ALDH1B1 autoantibody has a good potential for early detection of CRC and advanced adenoma, and measuring serum autoantibodies against tumor-associated antigens may improve detection of early CRC.
基金：
State Key Projects Specialized on Infectious Diseases [2017ZX10201201-007-002, 2017ZX10203202-004-007]; National Natural Science FoundationNational Natural Science Foundation of China (NSFC) [81703309]; CAMS Innovation Fund for Medical Science [2017-I2M-1-006]; Beijing Nova Program of Science and Technology [Z191100001119065]; Beijing Natural Science FoundationBeijing Natural Science Foundation [7202169]
第一作者单位：[1]Experimental Centre, Beijing Friendship Hospital, Capital Medical University, Beijing, China,
通讯作者：
通讯机构：[1]Experimental Centre, Beijing Friendship Hospital, Capital Medical University, Beijing, China,[3]National Clinical Research Center for Digestive Disease, Beijing Friendship Hospital, Capital Medical University, Beijing, China,
推荐引用方式(GB/T 7714)：
Hejing Wang,Bei Zhang,Xiaojin Li,et al.Identification and Validation of Novel Serum Autoantibody Biomarkers for Early Detection of Colorectal Cancer and Advanced Adenoma[J].FRONTIERS in ONCOLOGY.2020,10:doi:10.3389/fonc.2020.01081.
APA：
Hejing Wang,Bei Zhang,Xiaojin Li,Donghu Zhou,Yanmeng Li...&Jian Huang.(2020).Identification and Validation of Novel Serum Autoantibody Biomarkers for Early Detection of Colorectal Cancer and Advanced Adenoma.FRONTIERS in ONCOLOGY,10,
MLA：
Hejing Wang,et al."Identification and Validation of Novel Serum Autoantibody Biomarkers for Early Detection of Colorectal Cancer and Advanced Adenoma".FRONTIERS in ONCOLOGY 10.(2020)
